Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients

Immunopharmacology and Immunotoxicology

Volumn 36, Issue 3, 2014, Pages 224-236

  Kawano, Kouichiro ^a   Tsuda, Naotake ^a   Matsueda, Satoko ^a   Sasada, Tetsuro ^a   Watanabe, Noriko ^a   Ushijima, Kimio ^a   Yamaguchi, Tomohiko ^b   Yokomine, Masato ^a   Itoh, Kyogo ^a   Yamada, Akira ^c   Kamura, Toshiharu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

Cytotoxic T lymphocytes; Epitopes; Ovarian cancer; Peptide vaccine; Personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYPB 129 PEPTIDE VACCINE; EGFR 800 PEPTIDE VACCINE; EZH2 735 PEPTIDE VACCINE; HNRPL 140; HNRPL 140 PEPTIDE VACCINE; HNRPL 501; HNRPL 501 PEPTIDE VACCINE; LCK 208; LCK 208 PEPTIDE VACCINE; LCK 246 PEPTIDE VACCINE; LCK 422 PEPTIDE VACCINE; LCK 449; LCK 486; LCK 486 PEPTIDE VACCINE; LCK 488; LCK 488 PEPTIDE VACCINE; LCK 90; MONTANIDE ISA 51; MRP 3 503; MRP3 1293 PEPTIDE VACCINE; MRP3 503 PEPTIDE VACCINE; PAP 213; PAP 213 PEPTIDE VACCINE; PAP 248; PEPTIDE VACCINE; PPMAPKKK 432 PEPTIDE VACCINE; PSA 248 PEPTIDE VACCINE; PSMA 624; PSMA 624 PEPTIDE VACCINE; PTHRP 102 PEPTIDE VACCINE; SART 3 511; SART2 161 PEPTIDE VACCINE; SART3 109 PEPTIDE VACCINE; SART3 302 PEPTIDE VACCINE; SART3 309 PEPTIDE VACCINE; UBE 2V 43; UBE2V 43 PEPTIDE VACCINE; UBE2V 85 PEPTIDE VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WHSC 2 103; WHSC2 103 PEPTIDE VACCINE; WHSC2 141 PEPTIDE VACCINE; IMMUNOGLOBULIN G; PEPTIDE; TUMOR ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; HYPOALBUMINEMIA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE INFECTION; INJECTION SITE REACTION; INTESTINAL BLEEDING; LEG EDEMA; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PERSONALIZED PEPTIDE VACCINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; URETER OBSTRUCTION; VACCINATION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84901301005     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2014.913617     Document Type: Article

References (33)

1. Jermal A, Siegal R, Ward E, et al. Cancer stastatics, 2009. CA Cancer J Clin 2009;59:225-249
2. Ozosis R. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: DeVita VT, ed. Cancer, principles and practice of oncology. Philadelphia, PA: Lippincott-Raven; 1997:1502-1540
3. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19: 3312-3322. (Pubitemid 32642183
4. Yamada A, Kawano K, Harashima N, et al. Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer. Cancer Immunol Immunother 1999;48:147-152. (Pubitemid 29287300
5. Fisk B, Blevins TL, Wharton JT, et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-2117
6. Kawano K, Efferson CL, Peoples GE, et al. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death. Cancer Res 2005;65:2930-2937. (Pubitemid 40490098
7. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213. (Pubitemid 36077915
8. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:8538-8543
9. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune previlige and predicts reduced survival. Nat Med 2004;10:942-949. (Pubitemid 39273735
10. Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraeperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010;59:293-301
11. Hodi FS, Mihm MS, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-Associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712-4717. (Pubitemid 36457795
12. Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008;14:2740-2748
13. Aoki Y, Takakuwa K, Kodama S, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991;51:1934-1939
14. Chianese-Bullock KA, Irvin Jr WP, Petroni GR, et al. A multiple vaccine is safe and elicits T-cell responses in patients with advanced stage ovarian cancer. J Immunother 2008;31:420-430. (Pubitemid 351595165
15. Leffers N, Lambeck AJA, Gooden MJM, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients: A phase II trial. Int J Cancer 2009;125:2104-2113
16. Itoh K, Yamada A. Personalized peptide vaccines: A new therapeutic modality for cancer. Cancer Sci 2006;97:970-976. (Pubitemid 44322541
17. Terasaki M, Shibui S, Narita Y, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011;29:337-344
18. Yanagimoto H, Shiomi H, Satoi S, et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010;24: 795-801
19. Hattori T, Mine T, Komatsu N, et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009;58:1843-1852
20. Noguchi M, Kakuma T, Uemura H, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010;59:1001-1009
21. Mine T, Sato Y, Noguchi M, et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004;10:929-937. (Pubitemid 38198892
22. Noguchi M, Mine T, Komatsu N, et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011;10: 1266-1279
23. Yutani S, Komatsu N, Matsueda S, et al. Juzentaihoto failed to augment antigen-specific immunity but prevented deterioration of patients' conditions in advanced pancreatic cancer under personalized peptide vaccine. Evid Based Complement Alternat Med 2013; 2013:981717. doi: 10.1155/2013/981717
24. Komatsu N, Matsueda S, Tashiro K, et al. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 2012;118:3208-3221
25. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26: 890-896. (Pubitemid 351398081
26. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25:2811-2818. (Pubitemid 47123191
27. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and car boplatin vs paclitaxel and carboplatin in platinum-sensitiveovarian cancer patients. Br J Cancer 2012;107: 588-591
28. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-2045
29. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011;60:433-442
30. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102: 1388-1397
31. Amos SM, Duong CP, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011;118: 499-509
32. López MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumorspecific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 2009;27: 945-952
33. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369: 122-133